Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

NCT05177094 PHASE2 COMPLETED Results posted

The purpose of this study is to test the safety and efficacy of study drug LY3526318 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Details

Lead sponsor	Eli Lilly and Company
Phase	PHASE2
Status	COMPLETED
Enrolment	155
Start date	Wed Jan 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetic Peripheral Neuropathic Pain

Interventions

• LY3526318
• Placebo

Countries

Puerto Rico, United States